Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK; Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK.
Magn Reson Imaging. 2021 Feb;76:116-122. doi: 10.1016/j.mri.2020.11.011. Epub 2020 Nov 19.
Cardiac magnetic resonance imaging (MRI) is emerging as an important imaging tool in the assessment of heart failure with preserved ejection fraction (HFpEF). This systematic review and meta-analysis aim to synthesise and consolidate the current literature on cardiac MRI for prognostication of HFpEF.
Systematic review and meta-analysis.
Scopus (PubMed and Embase) for studies published between 2008 and 2019. Eligibility criteria for study selection were studies that evaluated the prognostic role of cardiac MRI in HFpEF. Random effects meta-analyses of the reported hazard ratios (HR) for clinical outcomes was performed.
Initial screening identified 97 studies. From these, only nine (9%) studies met all the criteria. The main cardiac MRI methods that demonstrated association to prognosis in HFpEF included late gadolinium enhancement (LGE) assessment of scar (n = 3), tissue characterisation with T1-mapping (n = 4), myocardial ischaemia (n = 1) and right ventricular dysfunction (RVSD) (n = 1). The pooled HR for all 9 studies was 1.52 (95% CI 1.05-1.99, P < 0.01). Sub-evaluation by cardiac MRI methods revealed varying HRs: LGE (net n = 402, HR = 1.6, 95% CI 0.42-2.78, P = 0.008); T1-mapping (n = 1623, HR = 1.25, 95% CI 0.891-1.60, P < 0.001); myocardial ischaemia or RVSD (n = 325, HR = 3.19, 95% CI 0.30-6.08, P = 0.03).
This meta-analysis demonstrates that multiparametric cardiac MRI has value in prognostication of patients with HFpEF. HFpEF patients with a detectable scar on LGE, fibrosis on T1-mapping, myocardial ischaemia or RVSD appear to have a worse prognosis.
CRD42020187228.
心脏磁共振成像(CMR)作为评估射血分数保留的心力衰竭(HFpEF)的重要成像工具正在兴起。本系统评价和荟萃分析旨在综合和整合当前关于 CMR 预测 HFpEF 的文献。
系统评价和荟萃分析。
2008 年至 2019 年在 Scopus(PubMed 和 Embase)上发表的研究。研究选择的纳入标准为评估 CMR 在 HFpEF 中预后作用的研究。对报告的临床结局风险比(HR)进行了随机效应荟萃分析。
初步筛选确定了 97 项研究。其中,只有 9 项(9%)研究符合所有标准。在 HFpEF 中与预后相关的主要心脏 MRI 方法包括晚期钆增强(LGE)评估瘢痕(n=3)、T1 映射的组织特征(n=4)、心肌缺血(n=1)和右心室功能障碍(RVSD)(n=1)。9 项研究的汇总 HR 为 1.52(95%CI 1.05-1.99,P<0.01)。通过心脏 MRI 方法进行的亚评估显示出不同的 HR:LGE(净 n=402,HR=1.6,95%CI 0.42-2.78,P=0.008);T1 映射(n=1623,HR=1.25,95%CI 0.891-1.60,P<0.001);心肌缺血或 RVSD(n=325,HR=3.19,95%CI 0.30-6.08,P=0.03)。
这项荟萃分析表明,多参数心脏 MRI 对 HFpEF 患者的预后具有价值。在 LGE 上可检测到瘢痕、T1 映射上纤维化、心肌缺血或 RVSD 的 HFpEF 患者预后较差。
PROSPERO 注册号:CRD42020187228。